POS1102 THE PREVALENCE OF INFLAMMATORY BACK PAIN IN PATIENTS WITH SKIN PSORIASIS WITHOUT PSORIATIC ARTHRITIS. DATA FROM DERMATOLOGICAL REAL-WORLD SETTING.

Background Psoriasis (PsO) is an inflammatory disease associated with psoriatic arthritis (PsA). PsA affects peripheral and axial joints 1,2 . can precede the onset of by approximately 3 to 8 years, involvement often undiagnosed There are limited data about prevalence back pain (IBP) in PsO patients (pts) without clinical symptoms 4 Objectives To study IBP pts Methods 108 over a 10-month period (March 2021 December 2021) were incluided. Participants filled out questionnaire on IBP. Additionaly stiffness neck was estimated. defined as affirmative answer question ‘Did you suffer from low for ?3 months?’ criteria based ASAS (the ASsessment Ankylosing Spondylitis) confirmed if at least following present: (a) before age 40, (b) insidious onset, (c) improvement exercise, (d) morning Results It found that more than 40% complained or back. Stiffness observed every fourth patient average. Of those who neck, 37% noted they had rest (when get up lie down long time), 21.3% night forced woke up, needed do exercises) (Table 1). risks developing spondylitis pain, stiffness, higher 4,549 times (95% CI [1,720; 12,031]), 19,444 [6,480; 58,343]) 15 [4.646; 48.427]) 34.857 [7.583; 160.230]), respectively. Conclusion patients. Every neck. The presence these significantly increased risk spondylitis. should be taken into account early diagnosis dermatological practice. References [1]Gladman DD. Axial arthritis. Curr Rheumatol Rep. 2007 Dec;9(6):455-60. doi: 10.1007/s11926-007-0074-2. [2]Chandran V, Barrett J, Schentag CT, Farewell VT, Gladman arthritis: update longterm prospective study. J Rheumatol. 2009 Dec;36(12):2744-50. 10.3899/jrheum.090412. [3]Queiro R, Belzunegui González C, De DJ, Sarasqueta Torre JC, Figueroa M. Clinically asymptomatic spondyloarthropathy. A retrospective Clin 2002 Feb;21(1):10-3. 10.1007/s100670200003. [4]Gottlieb AB, Merola JF. An dermatologists. Am Acad Dermatol. Jan;84(1):92-101. 10.1016/j.jaad.2020.05.089. Disclosure Interests Natalia Pereverzina: None declared, Larisa Kruglova: Tatiana Korotaeva Speakers bureau: Pfizer, MSD, AbbVie, Novartis-Sandoz, JSC Biocad, Janssen, UCB, Alexander Lila: declared